Clinical Trial Update: A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating apremilast 30 mg twice daily in Chinese adults with moderate to severe plaque psoriasis has been completed, assessing efficacy and safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Amgen | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED